|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000135914 |
Summary for HTR2B |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000135914 | Gene symbol | HTR2B |
| Gene name | 5-hydroxytryptamine receptor 2B | |
| HGNC | 5294 | |
| Entrez ID | 3357 | |
| Gene type | protein_coding | |
| Synonyms | HTR2B|5-HT(2B)|5-HT2B | |
| UniProtAcc | P41595 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| ENSG00000135914 | HTR2B | DB00247 | Methysergide | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB00248 | Cabergoline | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB00315 | Zolmitriptan | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB00320 | Dihydroergotamine | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB00353 | Methylergometrine | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB00434 | Cyproheptadine | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB00508 | Triflupromazine | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB00543 | Amoxapine | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB00574 | Fenfluramine | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB00589 | Lisuride | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB00696 | Ergotamine | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB00714 | Apomorphine | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB00715 | Paroxetine | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB00805 | Minaprine | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB00924 | Cyclobenzaprine | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB01079 | Tegaserod | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB01142 | Doxepin | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB01186 | Pergolide | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB01200 | Bromocriptine | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB01238 | Aripiprazole | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB01242 | Clomipramine | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB01392 | Yohimbine | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB01454 | Midomafetamine | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB04829 | Lysergic acid diethylamide | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB05461 | OPC-28326 | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB05492 | Epicept NP-1 | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB05607 | PRX-08066 | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB06016 | Cariprazine | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB06148 | Mianserin | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB06153 | Pizotifen | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB06216 | Asenapine | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB06229 | Ocaperidone | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB09286 | Pipamperone | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB00715 | Paroxetine | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB01049 | Ergoloid mesylate | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB01239 | Chlorprothixene | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB09304 | Setiptiline | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB11273 | Dihydroergocornine | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB12141 | Gilteritinib | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB13025 | Tiapride | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB13345 | Dihydroergocristine | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB00477 | Chlorpromazine | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB08804 | Nandrolone decanoate | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB01221 | Ketamine | SmallMoleculeDrug |
| ENSG00000135914 | HTR2B | DB06678 | Esmirtazapine | SmallMoleculeDrug |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
| ENSG00000135914 | HTR2B | DB12141 | Gilteritinib | SmallMoleculeDrug | Acute Myeloid Leukemia (AML) |
Top |
Structure and expression level for HTR2B |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| HTR2B | 1.47e+02 | 1.89e+00 | 2.20e-01 | 8.59e+00 | 8.95e-18 | 4.09e-15 | LIHC |
| Differentially expressed gene analysis between tumor male and normal male samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| HTR2B | 1.44e+02 | -1.48e+00 | 3.28e-01 | -4.51e+00 | 6.59e-06 | 2.11e-05 | KIRC |
Top |
Sex-biased somatic mutation for HTR2B |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for HTR2B |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg06096336 | chr2:231125086 | CGI:chr2:231056699-231057258 | UTR,promoter,exon,gene body | 5.30e-01 | 7.09e-01 | -2.47e+00 | 1.36e-02 | 3.00e-02 | -1.79e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| COAD | cg06096336 | chr2:231125086 | CGI:chr2:231056699-231057258 | UTR,promoter,exon,gene body | 7.86e-01 | 6.73e-01 | 3.82e+00 | 1.33e-04 | 4.40e-04 | 1.14e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg06096336 | chr2:231125086 | CGI:chr2:231056699-231057258 | UTR,promoter,exon,gene body | 5.30e-01 | 3.54e-01 | 7.81e+00 | 5.94e-15 | 2.16e-14 | 1.76e-01 |
| BRCA | cg04042861 | chr2:231125110 | CGI:chr2:231056699-231057258 | UTR,promoter,exon,gene body | 5.37e-01 | 2.91e-01 | 2.97e+00 | 2.93e-03 | 3.60e-03 | 2.46e-01 |
| LUAD | cg06096336 | chr2:231125086 | CGI:chr2:231056699-231057258 | UTR,promoter,exon,gene body | 6.74e-01 | 5.73e-01 | 2.10e+00 | 3.60e-02 | 3.94e-02 | 1.01e-01 |
| BLCA | cg04042861 | chr2:231125110 | CGI:chr2:231056699-231057258 | UTR,promoter,exon,gene body | 6.05e-01 | 3.01e-01 | 2.67e+00 | 7.64e-03 | 1.47e-02 | 3.04e-01 |
| LIHC | cg06096336 | chr2:231125086 | CGI:chr2:231056699-231057258 | UTR,promoter,exon,gene body | 7.63e-01 | 6.33e-01 | 4.64e+00 | 3.45e-06 | 3.18e-05 | 1.30e-01 |
| LIHC | cg04042861 | chr2:231125110 | CGI:chr2:231056699-231057258 | UTR,promoter,exon,gene body | 7.62e-01 | 6.42e-01 | 4.23e+00 | 2.36e-05 | 1.30e-04 | 1.21e-01 |
Top |
Exon skipping events with PSI in TCGA for HTR2B |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for HTR2B |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for HTR2B |
| TFs related to HTR2B. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| CHOL | ZNF225 | HTR2B | 3.39e+00 | 9.61e-03 | 4.33e+00 | 9.83e-01 | Female-biased |
| CHOL | ZNF570 | HTR2B | 4.17e+00 | 4.17e-03 | 5.33e+00 | 9.94e-01 | Female-biased |
| CHOL | ZNF879 | HTR2B | 3.61e+00 | 1.52e-03 | 5.02e+00 | 9.96e-01 | Female-biased |
| LAML | ZNF492 | HTR2B | 4.69e+00 | 1.67e-02 | 5.46e+00 | 9.81e-01 | Female-biased |
| LAML | ZNF570 | HTR2B | 5.51e+00 | 1.18e-02 | 6.37e+00 | 9.88e-01 | Female-biased |
| LAML | ZNF879 | HTR2B | 5.55e+00 | 1.08e-02 | 6.44e+00 | 9.89e-01 | Female-biased |
| PAAD | ZNF570 | HTR2B | 5.25e+00 | 9.85e-01 | 4.47e+00 | 1.33e-02 | Male-biased |
| PAAD | ZNF879 | HTR2B | 4.80e+00 | 9.90e-01 | 3.86e+00 | 5.65e-03 | Male-biased |
| SARC | ZNF570 | HTR2B | 4.34e+00 | 1.44e-02 | 4.92e+00 | 9.82e-01 | Female-biased |
| SARC | ZNF879 | HTR2B | 3.44e+00 | 7.39e-03 | 4.13e+00 | 9.81e-01 | Female-biased |
| THYM | ZNF225 | HTR2B | 5.16e+00 | 1.71e-02 | 5.72e+00 | 9.82e-01 | Female-biased |
| THYM | ZNF235 | HTR2B | 4.67e+00 | 1.72e-02 | 5.24e+00 | 9.80e-01 | Female-biased |
| THYM | ZNF492 | HTR2B | 4.92e+00 | 1.62e-02 | 5.50e+00 | 9.82e-01 | Female-biased |
| THYM | ZNF570 | HTR2B | 5.67e+00 | 9.06e-03 | 6.38e+00 | 9.90e-01 | Female-biased |
| THYM | ZNF879 | HTR2B | 5.67e+00 | 6.69e-03 | 6.46e+00 | 9.93e-01 | Female-biased |
| HTR2B related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for HTR2B |
| RBPs related to ES in HTR2B. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| HTR2B related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs2270854 | chr2:233832755:C:T | - | 0.135399925501301 | 0.000721360273759828 | SARC | Female-baised eQTL |
| rs2270856 | chr2:233833162:C:T | - | 0.127151120219367 | 0.00178171431183078 | SARC | Female-baised eQTL |
| rs13416326 | chr2:233836015:A:G | - | 0.126661769369027 | 0.00191508469767652 | SARC | Female-baised eQTL |
| rs4337431 | chr2:234780776:C:T | - | 0.0713646667747556 | 0.0439115523141272 | SARC | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs1463560 | chr2:230484173:A:G | - | 0.107349880726071 | 0.000254941502337259 | LUAD | Male-baised eQTL |
| rs10929133 | chr2:235461075:C:A | - | 0.0792915107168178 | 0.000401312579184823 | LUAD | Male-baised eQTL |
| rs10221771 | chr2:235461312:T:C | - | 0.0760292137052604 | 0.000850989582970881 | LUAD | Male-baised eQTL |
| rs10205568 | chr2:230266306:A:G | - | 0.109175057411361 | 0.00687215989586717 | LUAD | Male-baised eQTL |
| rs59548048 | chr2:230308016:C:G | - | 0.126099082692407 | 0.0110111395038239 | LUAD | Male-baised eQTL |
| rs7602895 | chr2:235470767:T:C | - | 0.0863045692474207 | 0.0203301513489053 | LUAD | Male-baised eQTL |
| rs57125832 | chr2:235481850:G:C | - | 0.0862337313386364 | 0.0206536343149602 | LUAD | Male-baised eQTL |
| rs28376167 | chr2:233258021:C:A | - | 0.060241755001409 | 0.022853318873208 | LUAD | Male-baised eQTL |
| rs113703895 | chr2:234299771:T:C | - | 0.0940129570752106 | 0.0243283459957384 | LUAD | Male-baised eQTL |
| rs28554073 | chr2:233258029:C:A | - | 0.0597532636843367 | 0.0247104443574268 | LUAD | Male-baised eQTL |
| rs13388025 | chr2:233255518:T:A | - | 0.0583202171839224 | 0.0305972506850819 | LUAD | Male-baised eQTL |
| rs6758145 | chr2:233256511:A:T | - | 0.0583202171839224 | 0.0305972506850819 | LUAD | Male-baised eQTL |
| rs12469274 | chr2:230317173:T:A | - | 0.0588556262246408 | 0.0327186210995583 | LUAD | Male-baised eQTL |
| rs1010491 | chr2:230295806:A:G | - | 0.107367332003882 | 0.0331600774001616 | LUAD | Male-baised eQTL |
| rs72990219 | chr2:230301221:C:T | - | 0.107367332003882 | 0.0331600774001616 | LUAD | Male-baised eQTL |
| rs72990227 | chr2:230305664:C:A | - | 0.107284066987035 | 0.0335250901526423 | LUAD | Male-baised eQTL |
| rs55796826 | chr2:230284123:G:A | - | 0.107224322955537 | 0.0338366519058343 | LUAD | Male-baised eQTL |
| rs2119503 | chr2:233257131:G:A | - | 0.0575915828829069 | 0.034147089055863 | LUAD | Male-baised eQTL |
| rs36144939 | chr2:230501588:C:G | - | 0.0596866712796383 | 0.0393785912115917 | LUAD | Male-baised eQTL |
| rs4429463 | chr2:231018632:G:C | - | 0.0681101881507479 | 0.0441859682648916 | LUAD | Male-baised eQTL |
| rs72988209 | chr2:230250809:A:T | - | 0.102387696486212 | 0.0451252303155133 | LUAD | Male-baised eQTL |
| rs7580840 | chr2:230320704:G:A | - | 0.0545776404908552 | 0.048548193838496 | LUAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000135914 |
| CpG Site: cg06096336 | |
| Position to Gene: gene,exon,promoter,UTR | |
| Male Effect: - | |
| Female Effect: -0.268064155468772 |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg06096336 | chr2:231125086 | gene,exon,promoter,UTR | -0.268064155468772 | 1.7195100162008e-24 | -0.6185398251050612 | 2.5900578729878615e-28 | LUAD |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of HTR2B |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000135914 | HTR2B | C0013221 | Drug toxicity | 1 | CTD_human |
| ENSG00000135914 | HTR2B | C0018800 | Cardiomegaly | 3 | CTD_human |
| ENSG00000135914 | HTR2B | C0018801 | Heart failure | 1 | CTD_human |
| ENSG00000135914 | HTR2B | C0018802 | Congestive heart failure | 1 | CTD_human |
| ENSG00000135914 | HTR2B | C0018824 | Heart valve disease | 4 | CTD_human |
| ENSG00000135914 | HTR2B | C0020538 | Hypertensive disease | 1 | CTD_human |
| ENSG00000135914 | HTR2B | C0020542 | Pulmonary Hypertension | 1 | CTD_human |
| ENSG00000135914 | HTR2B | C0023212 | Left-Sided Heart Failure | 1 | CTD_human |
| ENSG00000135914 | HTR2B | C0041755 | Adverse reaction to drug | 1 | CTD_human |
| ENSG00000135914 | HTR2B | C0235527 | Heart Failure, Right-Sided | 1 | CTD_human |
| ENSG00000135914 | HTR2B | C1383860 | Cardiac Hypertrophy | 3 | CTD_human |
| ENSG00000135914 | HTR2B | C1959583 | Myocardial Failure | 1 | CTD_human |
| ENSG00000135914 | HTR2B | C1961112 | Heart Decompensation | 1 | CTD_human |
